<?xml version='1.0' encoding='utf-8'?>
<document id="20821385"><sentence text="Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma."><entity charOffset="15-19" id="DDI-PubMed.20821385.s1.e0" text="PLGA" /><entity charOffset="61-72" id="DDI-PubMed.20821385.s1.e1" text="vincristine" /><entity charOffset="77-86" id="DDI-PubMed.20821385.s1.e2" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.20821385.s1.e0" e2="DDI-PubMed.20821385.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s1.e0" e2="DDI-PubMed.20821385.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s1.e0" e2="DDI-PubMed.20821385.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s1.e1" e2="DDI-PubMed.20821385.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s1.e1" e2="DDI-PubMed.20821385.s1.e2" /></sentence><sentence text="Hepatocellular carcinoma (HCC) is one of the malignant tumors with poor chemo-sensitivity to vincristine sulfate (VCR) due to multi-drug resistance (MDR)"><entity charOffset="93-112" id="DDI-PubMed.20821385.s2.e0" text="vincristine sulfate" /><entity charOffset="114-117" id="DDI-PubMed.20821385.s2.e1" text="VCR" /><pair ddi="false" e1="DDI-PubMed.20821385.s2.e0" e2="DDI-PubMed.20821385.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s2.e0" e2="DDI-PubMed.20821385.s2.e1" /></sentence><sentence text=" Combinations of encapsulated VCR and verapamil hydrochloride (VRP, a chemo-sensitizer) might be a potential strategy to improve HCC therapeutic efficacy of VCR"><entity charOffset="38-61" id="DDI-PubMed.20821385.s3.e0" text="verapamil hydrochloride" /><entity charOffset="63-66" id="DDI-PubMed.20821385.s3.e1" text="VRP" /><entity charOffset="30-32" id="DDI-PubMed.20821385.s3.e2" text="VCR" /><entity charOffset="157-159" id="DDI-PubMed.20821385.s3.e3" text="VCR" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e2" e2="DDI-PubMed.20821385.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e2" e2="DDI-PubMed.20821385.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e2" e2="DDI-PubMed.20821385.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e2" e2="DDI-PubMed.20821385.s3.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e0" e2="DDI-PubMed.20821385.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e0" e2="DDI-PubMed.20821385.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e0" e2="DDI-PubMed.20821385.s3.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e1" e2="DDI-PubMed.20821385.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s3.e1" e2="DDI-PubMed.20821385.s3.e3" /></sentence><sentence text=" PLGA nanoparticles (PLGANPs) simultaneously loaded with VCR and VRP (CVn) were prepared"><entity charOffset="1-3" id="DDI-PubMed.20821385.s4.e0" text="PLGA" /><entity charOffset="21-23" id="DDI-PubMed.20821385.s4.e1" text="PLGA" /><entity charOffset="57-59" id="DDI-PubMed.20821385.s4.e2" text="VCR" /><entity charOffset="65-67" id="DDI-PubMed.20821385.s4.e3" text="VRP" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e0" e2="DDI-PubMed.20821385.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e0" e2="DDI-PubMed.20821385.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e0" e2="DDI-PubMed.20821385.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e0" e2="DDI-PubMed.20821385.s4.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e1" e2="DDI-PubMed.20821385.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e1" e2="DDI-PubMed.20821385.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e1" e2="DDI-PubMed.20821385.s4.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e2" e2="DDI-PubMed.20821385.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s4.e2" e2="DDI-PubMed.20821385.s4.e3" /></sentence><sentence text=" The entrapment efficiencies of VCR and VRP were 70"><entity charOffset="32-34" id="DDI-PubMed.20821385.s5.e0" text="VCR" /><entity charOffset="40-42" id="DDI-PubMed.20821385.s5.e1" text="VRP" /><pair ddi="false" e1="DDI-PubMed.20821385.s5.e0" e2="DDI-PubMed.20821385.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s5.e0" e2="DDI-PubMed.20821385.s5.e1" /></sentence><sentence text="92 ± 3" /><sentence text="78% and 85" /><sentence text="78 ± 3" /><sentence text="23%, respectively (n = 3)" /><sentence text=" The HCC therapeutic activity of CVn was assessed using MTT assay"><entity charOffset="56-59" id="DDI-PubMed.20821385.s10.e0" text="MTT" /></sentence><sentence text=" In BEL7402 and BEL7402/5-FU human hepatocarcinoma cell lines, CVn had the same antitumor effect as one free drug/another agent-loaded PLGANPs (C + Vn or Cn + V) combination and coadministration of two single-agent-loaded PLGANPs (Cn + Vn), which was slightly higher than that of the free VCR/VRP combination (C - V)"><entity charOffset="4-11" id="DDI-PubMed.20821385.s11.e0" text="BEL7402" /><entity charOffset="16-23" id="DDI-PubMed.20821385.s11.e1" text="BEL7402" /><entity charOffset="144-150" id="DDI-PubMed.20821385.s11.e2" text="C + Vn" /><entity charOffset="231-238" id="DDI-PubMed.20821385.s11.e3" text="Cn + Vn" /><entity charOffset="135-141" id="DDI-PubMed.20821385.s11.e4" text="PLGA" /><entity charOffset="222-228" id="DDI-PubMed.20821385.s11.e5" text="PLGA" /><entity charOffset="289-295" id="DDI-PubMed.20821385.s11.e6" text="VCR" /><entity charOffset="293-299" id="DDI-PubMed.20821385.s11.e7" text="VRP" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e0" e2="DDI-PubMed.20821385.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e1" e2="DDI-PubMed.20821385.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e4" e2="DDI-PubMed.20821385.s11.e4" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e4" e2="DDI-PubMed.20821385.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e4" e2="DDI-PubMed.20821385.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e4" e2="DDI-PubMed.20821385.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e4" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e4" e2="DDI-PubMed.20821385.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e2" e2="DDI-PubMed.20821385.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e2" e2="DDI-PubMed.20821385.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e2" e2="DDI-PubMed.20821385.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e2" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e2" e2="DDI-PubMed.20821385.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e5" e2="DDI-PubMed.20821385.s11.e5" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e5" e2="DDI-PubMed.20821385.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e5" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e5" e2="DDI-PubMed.20821385.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e3" e2="DDI-PubMed.20821385.s11.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e3" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e3" e2="DDI-PubMed.20821385.s11.e7" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e6" e2="DDI-PubMed.20821385.s11.e6" /><pair ddi="false" e1="DDI-PubMed.20821385.s11.e6" e2="DDI-PubMed.20821385.s11.e7" /></sentence><sentence text=" CVn might cause lower normal tissue drug toxicity by the enhanced permeation and retention effect in vivo" /><sentence text=" Additionally, CVn might cause fewer drug-drug interaction and be the most potential formulation to simultaneously deliver VCR and VRP to the target cell in vivo than the other three nanoparticle formulations (C + Vn, Cn + V, and Cn + Vn)"><entity charOffset="210-216" id="DDI-PubMed.20821385.s13.e0" text="C + Vn" /><entity charOffset="218-224" id="DDI-PubMed.20821385.s13.e1" text="Cn + V" /><entity charOffset="230-237" id="DDI-PubMed.20821385.s13.e2" text="Cn + Vn" /><entity charOffset="123-129" id="DDI-PubMed.20821385.s13.e3" text="VCR" /><entity charOffset="131-137" id="DDI-PubMed.20821385.s13.e4" text="VRP" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e3" e2="DDI-PubMed.20821385.s13.e3" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e3" e2="DDI-PubMed.20821385.s13.e4" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e3" e2="DDI-PubMed.20821385.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e3" e2="DDI-PubMed.20821385.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e3" e2="DDI-PubMed.20821385.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e4" e2="DDI-PubMed.20821385.s13.e4" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e4" e2="DDI-PubMed.20821385.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e4" e2="DDI-PubMed.20821385.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e4" e2="DDI-PubMed.20821385.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e0" e2="DDI-PubMed.20821385.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e0" e2="DDI-PubMed.20821385.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e0" e2="DDI-PubMed.20821385.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e1" e2="DDI-PubMed.20821385.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20821385.s13.e1" e2="DDI-PubMed.20821385.s13.e2" /></sentence><sentence text=" Therefore, we speculate that CVn might be the most effective preparation in the treatment of drug-resistant human HCC in vivo" /><sentence text="" /></document>